Adjustments to Diabetes Medications in Response to Increases in Hemoglobin A1c: An Epidemiologic Study

Annals of Pharmacotherapy

Volumn 48, Issue 1, 2014, Pages 41-47

  Davis, James ^a   Chavez, Benjamin ^b,c   Juarez, Deborah T ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

^c PACIFIC UNIVERSITY   (United States)

Author keywords

clinical inertia; diabetes; HbA1c; medication adjustment

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; DIABETIC PATIENT; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT RESPONSE;

CLINICAL INERTIA; DIABETES; HBA1C; MEDICATION ADJUSTMENT;

AGED; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; FEMALE; HAWAII; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 84892870037     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013517870     Document Type: Article

References (32)

1. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011:.
2. American Diabetes Association Executive summary: standards of medical care in diabetes-2012. Diabetes Care. 2012;35(suppl 1):S4-S10. http://care.diabetesjournals.org/content/35/Supplement_1/S4.full. Accessed December 3, 2013.
3. Stratton IM,Adler AI,Neil HA, et al.Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.BMJ. 2000;321:405-412.
4. Reichard P,Nilsson B-Y,Rosenqvist U.The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.N Engl J Med. 1993;329:304-309.
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med. 1993;329:977-986.
6. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.N Engl J Med. 2005;353:2643-2653.
7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet. 1998;352:854-856.
8. Hoerger TJ,Segel JE,Gregg EW,Saaddine JB.Is glycemic control improving in U.S. adults?.Diabetes Care. 2008;31:81-86.
9. Clark DO,Von Korff MV,Saunders K, et al.A chronic disease score with empirically derived weights.Med Care. 1995;33:783-795.
10. Ratanawongsa N,Crosson JC,Schillinger D,Karter AJ,Saha CK,Marrero DG.Getting under the skin of clinical inertia in insulin initiation: the Translating 11. Research into Action for Diabetes (TRIAD) Insulin Starts Project.Diabetes Educ. 2012;38:94-100.
11. Petznick AM.Identifying and addressing barriers to insulin acceptance and adherence in patients with type 2 diabetes mellitus.J Am Osteopath Assoc. 2013;113:S6-S16.
12. Ross SA,Tildesley HD,Ashkenas J.Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes.Curr Med Res Opin. 2011;27:13-20.
13. Karter AJ,Subramanian U,Saha C, et al.Barriers to insulin initiation: the translating research into action for diabetes insulin starts project.Diabetes Care. 2010;33:733-735.
14. Ishii H,Iwamoto Y,Tajima N.An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes And Needs (DAWN) JAPAN study.PLoS One. 2012;7 (6): e36361.
15. LANTUS (insulin glargine) injection, solution [patient package insert]. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a#nlm42230-3. Accessed June 5, 2013.
16. Phillips LS,Branch WT,Cook CB, et al.Clinical inertia.Ann Intern Med. 2001;135:825-834.
17. Phillips LS,Ziemer DC,Doyle JP, et al.An endocrinologist-supported intervention aimed at providers improves diabetes management in a primary care site.Diabetes Care. 2005;28:2352-2360.
18. Miller CD,Barnes CS,Phillips LS, et al.Rapid A1c availability improves clinical decision-making in an urban primary care clinic.Diabetes Care. 2003;26:1158-1163.
19. Shah BR,Hux JE,Laupacis A,Zinman B,van Walraven C.Clinical inertia in response to inadequate glycemic control.Diabetes Care. 2005;28:600-606.
20. Grant R,Adams AS,Trinacty CM, et al.Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management.Diabetes Care. 2007;30:807-812.
21. Grant RW,Buse JB,Meigs JB.Quality of diabetes care in U.S. academic medical centers.Diabetes Care. 2005;28:337-442.
22. Rodondi N,Peng T,Karter AJ, et al.Ann Intern Med. 2006;144:475-484.
23. Avignon A,Attali C,Sultan A,Ferrat E,Le Breton J.Clinical inertia: viewpoints of general practitioners and diabetologists.Diabetes Metab. 2012;38:S53-S58.
24. Brennan TA,Dollear TJ,Hu M, et al.An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients.Health Aff (Millwood). 2012;31:120-129.
25. Gerber BS,Rapacki L,Castillo A, et al.Design of a trial to evaluate the impact of clinical pharmacists and community health promoters working with African-Americans and Latinos with diabetes.BMC Public Health. 2012;12:891.
26. Iyer R,Coderre P,McKelvey T, et al.An employer-based, pharmacist intervention model for patients with type 2 diabetes.Am J Health Syst Pharm. 2010;67:312-316.
27. Rochester CD,Leon N,Dombrowski R,Haines ST.Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus.Am J Health Syst Pharm. 2010;67:42-48.
28. Taveira TH,Friedmann PD,Cohen LB, et al.Pharmacist-led group medical appointment model in type 2 diabetes.Diabetes Educ. 2010;36:109-117.
29. Lee WC,Balu S,Cobden D,Joshi AV,Pashos CL.Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review.Manag Care Interface. 2006;288:2868-2879.
30. Kirwin JL,Cunningham RJ,Sequist TD.Pharmacist recommendations to improve the quality of diabetes care: a randomized controlled trial.J Manag Care Pharm. 2010;16:104-113.
31. Cohen L,Tavira TH,Khatana SA,Dooley AG,Pirraglia PA,Wu WC.Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes.Diabetes Educ. 2011;37:801-812.
32. Padiyara RS,D'Souza JJ,Rihani RS.Clinical pharmacist intervention and the proportion of diabetes patients attaining prevention objectives in a multispecialty medical group.J Manag Care Pharm. 2011;17:456-462.